ArticleNPJ precision oncology2025
Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC.
Masayuki Shirasawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it